Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis

Clinical Infectious Diseases

Volumn 44, Issue 9, 2007, Pages 1180-1186

  Anavekar, Nandan S ^a,d   Tleyjeh, Imad M ^a,c   Anavekar, Nanesh S ^b   Mirzoyev, Zaur ^a   Steckelberg, James M ^a   Haddad, Christopher ^a   Khandaker, Masud H ^a   Wilson, Walter R ^a   Chandrasekaran, Krishnaswamy ^a   Baddour, Larry M ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; EMBOLISM; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT OUTCOME; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; INCIDENCE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT;

AGED; ASPIRIN; CEREBROVASCULAR ACCIDENT; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMBOLISM; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TICLOPIDINE;

EID: 34247251422     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513197     Document Type: Article

References (40)

1. Sanfilippo AJ, Picard MH, Newell JB, et al. Echocardiography assessment of patients with infectious endocarditis: prediction of risk for complications. J Am Coll Cardiol 1991; 18:1191-9.
2. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-434.
3. Delahaye JP, Ponlet P, Malquarti V, Beaune J, Gare JP, Man JM. Cerebrovascular accidents in infective endocarditis: role of anticoagulation. Eur Heart J 1990; 11:1074-8.
4. Heiro M, Nikoskelainen J, Engbolm E, Kotilainen E, Marttila R, Kotilainen, P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med 2000; 160:2781-7.
5. Kupferwasser LI, Yeaman MR, Shapiro SM, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999; 99:2791-7.
6. Kupferwasser LI, Yeaman MR, Nast CC, et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest 2003; 112:222-33.
7. Nicolau DP, Freeman CD, Nightingale CH, et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun 1993; 61:1593-5.
8. Nicolau DP, Marangus MN, Nightingale CH, Quintiliani R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1995; 39:1748-51.
9. Nicolau DP, Tessier PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 1999; 11:159-61.
10. Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 1998; 9:227-9.
11. Taha TH, Durrant SS, Mazeika PK, Nihoyannopoulos P, Oakley CM. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med 1992; 231:543-6.
12. Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol 2003; 42:775-80.
13. Li JS, Seaton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633-8.
14. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54:541-53.
15. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-63.
16. Farber BF, Wolff AG. The use of nonsteroidal antiinflammatory drugs to prevent adherence of Staphylococcus epidermidis to medical polymers. J Infect Dis 1992; 166:861-5.
17. Domenico P, Schwartz S, Cunha BA. Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun 1989; 57:3778-82.
18. Polonio RE, Mermel LA, Paquette GE, Sperry JF. Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin. Antimicrob Agents Chemother 2001; 45:3262-6.
19. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3:1309-11.
20. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review, aspirin resistance and its clinical implications. Ann Intern Med 2005; 142:370-80.
21. Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):234S-64S.
22. Weber AA, Liesener S, Schanz A, Hohlfeld T, Schror K. Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects. Platelets 2000; 11:177-82.
23. Cipollone F, Ciabattoni G, Patrigani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102:1007-13.
24. Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, Ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 2003; 327:1322-3.
25. Kurth T, Glyn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108:1191-5.
26. MacDonald TM, Wei L. Effect of Ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:573-4.
27. Schafer AI. Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation 2003; 108:910-1.
28. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14:51-8.
29. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001; 87:1361-6.
30. Fabri J Jr, Issa VS, Pomerantzeff PM, Grinberg M, Barrette AC, Mansur AJ. Time-related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis. Int J Cardiol 2006; 110:334-9.
31. Garvey GJ, Neu HC. Infective endocarditis: an evolving disease: a review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973. Medicine (Baltimore) 1978; 57:105-27.
32. Siddiq S, Missri J, Silverman DI. Endocarditis in an urban hospital in the 1990s. Arch Intern Med 1996; 156:2454-8.
33. Di Salvo G, Habib G, Pergola V, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 2001; 37:1069-76.
34. Lien EA, Solberg CO, Kalager T. Infective endocarditis 1973-1984 at the Bergen University Hospital: clinical feature, treatment and prognosis. Scand J Infect Dis 1988; 20:239-46.
35. Yusuf SW, Ali SS, Swafford J, et al. Culture-positive and culture-negative endocarditis in patients with cancer: a retrospective observational study, 1994-2004. Medicine 2006; 85:86-94.
36. Steckelberg JM, Melton LJ 3rd, Ilstrup DM, Rouse MS, Wilson WR. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am J Med 1990; 88:582-8.
37. Tleyjeh IM, Steckelberg JM, Murad HS, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA 2005; 293:3022-8.
38. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991; 325:1261-6.
39. Weinberger, J. Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Drugs 2005; 65:461-71.
40. Hill, AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58:295-300.